
Long-acting DPP-4 Inhibitor Drug Industry Research Report 2025
Description
Summary
According to APO Research, The global Long-acting DPP-4 Inhibitor Drug market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Long-acting DPP-4 Inhibitor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Long-acting DPP-4 Inhibitor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Long-acting DPP-4 Inhibitor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Long-acting DPP-4 Inhibitor Drug include Easton Biopharmaceuticals, Takeda Pharmaceutical, Merck & Co, Kelun Pharmaceutical, Haisco Pharmaceutical, Beacon Pharma, Baiji Dichang Pharmaceutical and Furiex, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Long-acting DPP-4 Inhibitor Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-acting DPP-4 Inhibitor Drug.
The Long-acting DPP-4 Inhibitor Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Long-acting DPP-4 Inhibitor Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Long-acting DPP-4 Inhibitor Drug Segment by Company
Easton Biopharmaceuticals
Takeda Pharmaceutical
Merck & Co
Kelun Pharmaceutical
Haisco Pharmaceutical
Beacon Pharma
Baiji Dichang Pharmaceutical
Furiex
Long-acting DPP-4 Inhibitor Drug Segment by Type
Weekly
Biweekly
Long-acting DPP-4 Inhibitor Drug Segment by Application
Hospital
Clinic
Others
Long-acting DPP-4 Inhibitor Drug Segment by Application
Hospital
Clinic
Others
Long-acting DPP-4 Inhibitor Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting DPP-4 Inhibitor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Long-acting DPP-4 Inhibitor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting DPP-4 Inhibitor Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Long-acting DPP-4 Inhibitor Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global Long-acting DPP-4 Inhibitor Drug market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Long-acting DPP-4 Inhibitor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Long-acting DPP-4 Inhibitor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Long-acting DPP-4 Inhibitor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Long-acting DPP-4 Inhibitor Drug include Easton Biopharmaceuticals, Takeda Pharmaceutical, Merck & Co, Kelun Pharmaceutical, Haisco Pharmaceutical, Beacon Pharma, Baiji Dichang Pharmaceutical and Furiex, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Long-acting DPP-4 Inhibitor Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-acting DPP-4 Inhibitor Drug.
The Long-acting DPP-4 Inhibitor Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Long-acting DPP-4 Inhibitor Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Long-acting DPP-4 Inhibitor Drug Segment by Company
Easton Biopharmaceuticals
Takeda Pharmaceutical
Merck & Co
Kelun Pharmaceutical
Haisco Pharmaceutical
Beacon Pharma
Baiji Dichang Pharmaceutical
Furiex
Long-acting DPP-4 Inhibitor Drug Segment by Type
Weekly
Biweekly
Long-acting DPP-4 Inhibitor Drug Segment by Application
Hospital
Clinic
Others
Long-acting DPP-4 Inhibitor Drug Segment by Application
Hospital
Clinic
Others
Long-acting DPP-4 Inhibitor Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting DPP-4 Inhibitor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Long-acting DPP-4 Inhibitor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting DPP-4 Inhibitor Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Long-acting DPP-4 Inhibitor Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
119 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Long-acting DPP-4 Inhibitor Drug by Type
- 2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
- 2.2.2 Weekly
- 2.2.3 Biweekly
- 2.3 Long-acting DPP-4 Inhibitor Drug by Application
- 2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.3.4 Others
- 2.4 Assumptions and Limitations
- 3 Long-acting DPP-4 Inhibitor Drug Breakdown Data by Type
- 3.1 Global Long-acting DPP-4 Inhibitor Drug Historic Market Size by Type (2020-2025)
- 3.2 Global Long-acting DPP-4 Inhibitor Drug Forecasted Market Size by Type (2026-2031)
- 4 Long-acting DPP-4 Inhibitor Drug Breakdown Data by Application
- 4.1 Global Long-acting DPP-4 Inhibitor Drug Historic Market Size by Application (2020-2025)
- 4.2 Global Long-acting DPP-4 Inhibitor Drug Forecasted Market Size by Application (2026-2031)
- 5 Global Growth Trends
- 5.1 Global Long-acting DPP-4 Inhibitor Drug Market Perspective (2020-2031)
- 5.2 Global Long-acting DPP-4 Inhibitor Drug Growth Trends by Region
- 5.2.1 Global Long-acting DPP-4 Inhibitor Drug Market Size by Region: 2020 VS 2024 VS 2031
- 5.2.2 Long-acting DPP-4 Inhibitor Drug Historic Market Size by Region (2020-2025)
- 5.2.3 Long-acting DPP-4 Inhibitor Drug Forecasted Market Size by Region (2026-2031)
- 5.3 Long-acting DPP-4 Inhibitor Drug Market Dynamics
- 5.3.1 Long-acting DPP-4 Inhibitor Drug Industry Trends
- 5.3.2 Long-acting DPP-4 Inhibitor Drug Market Drivers
- 5.3.3 Long-acting DPP-4 Inhibitor Drug Market Challenges
- 5.3.4 Long-acting DPP-4 Inhibitor Drug Market Restraints
- 6 Market Competitive Landscape by Players
- 6.1 Global Top Long-acting DPP-4 Inhibitor Drug Players by Revenue
- 6.1.1 Global Top Long-acting DPP-4 Inhibitor Drug Players by Revenue (2020-2025)
- 6.1.2 Global Long-acting DPP-4 Inhibitor Drug Revenue Market Share by Players (2020-2025)
- 6.2 Global Long-acting DPP-4 Inhibitor Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Long-acting DPP-4 Inhibitor Drug Head Office and Area Served
- 6.4 Global Long-acting DPP-4 Inhibitor Drug Players, Product Type & Application
- 6.5 Global Long-acting DPP-4 Inhibitor Drug Manufacturers Established Date
- 6.6 Global Long-acting DPP-4 Inhibitor Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
- 7 North America
- 7.1 North America Long-acting DPP-4 Inhibitor Drug Market Size (2020-2031)
- 7.2 North America Long-acting DPP-4 Inhibitor Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 7.3 North America Long-acting DPP-4 Inhibitor Drug Market Size by Country (2020-2025)
- 7.4 North America Long-acting DPP-4 Inhibitor Drug Market Size by Country (2026-2031)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
- 8 Europe
- 8.1 Europe Long-acting DPP-4 Inhibitor Drug Market Size (2020-2031)
- 8.2 Europe Long-acting DPP-4 Inhibitor Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 8.3 Europe Long-acting DPP-4 Inhibitor Drug Market Size by Country (2020-2025)
- 8.4 Europe Long-acting DPP-4 Inhibitor Drug Market Size by Country (2026-2031)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
- 9 Asia-Pacific
- 9.1 Asia-Pacific Long-acting DPP-4 Inhibitor Drug Market Size (2020-2031)
- 9.2 Asia-Pacific Long-acting DPP-4 Inhibitor Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 9.3 Asia-Pacific Long-acting DPP-4 Inhibitor Drug Market Size by Country (2020-2025)
- 9.4 Asia-Pacific Long-acting DPP-4 Inhibitor Drug Market Size by Country (2026-2031)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
- 10 South America
- 10.1 South America Long-acting DPP-4 Inhibitor Drug Market Size (2020-2031)
- 10.2 South America Long-acting DPP-4 Inhibitor Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 10.3 South America Long-acting DPP-4 Inhibitor Drug Market Size by Country (2020-2025)
- 10.4 South America Long-acting DPP-4 Inhibitor Drug Market Size by Country (2026-2031)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
- 11 Middle East & Africa
- 11.1 Middle East & Africa Long-acting DPP-4 Inhibitor Drug Market Size (2020-2031)
- 11.2 Middle East & Africa Long-acting DPP-4 Inhibitor Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 11.3 Middle East & Africa Long-acting DPP-4 Inhibitor Drug Market Size by Country (2020-2025)
- 11.4 Middle East & Africa Long-acting DPP-4 Inhibitor Drug Market Size by Country (2026-2031)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
- 12 Players Profiled
- 12.1 Easton Biopharmaceuticals
- 12.1.1 Easton Biopharmaceuticals Company Information
- 12.1.2 Easton Biopharmaceuticals Business Overview
- 12.1.3 Easton Biopharmaceuticals Revenue in Long-acting DPP-4 Inhibitor Drug Business (2020-2025)
- 12.1.4 Easton Biopharmaceuticals Long-acting DPP-4 Inhibitor Drug Product Portfolio
- 12.1.5 Easton Biopharmaceuticals Recent Developments
- 12.2 Takeda Pharmaceutical
- 12.2.1 Takeda Pharmaceutical Company Information
- 12.2.2 Takeda Pharmaceutical Business Overview
- 12.2.3 Takeda Pharmaceutical Revenue in Long-acting DPP-4 Inhibitor Drug Business (2020-2025)
- 12.2.4 Takeda Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio
- 12.2.5 Takeda Pharmaceutical Recent Developments
- 12.3 Merck & Co
- 12.3.1 Merck & Co Company Information
- 12.3.2 Merck & Co Business Overview
- 12.3.3 Merck & Co Revenue in Long-acting DPP-4 Inhibitor Drug Business (2020-2025)
- 12.3.4 Merck & Co Long-acting DPP-4 Inhibitor Drug Product Portfolio
- 12.3.5 Merck & Co Recent Developments
- 12.4 Kelun Pharmaceutical
- 12.4.1 Kelun Pharmaceutical Company Information
- 12.4.2 Kelun Pharmaceutical Business Overview
- 12.4.3 Kelun Pharmaceutical Revenue in Long-acting DPP-4 Inhibitor Drug Business (2020-2025)
- 12.4.4 Kelun Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio
- 12.4.5 Kelun Pharmaceutical Recent Developments
- 12.5 Haisco Pharmaceutical
- 12.5.1 Haisco Pharmaceutical Company Information
- 12.5.2 Haisco Pharmaceutical Business Overview
- 12.5.3 Haisco Pharmaceutical Revenue in Long-acting DPP-4 Inhibitor Drug Business (2020-2025)
- 12.5.4 Haisco Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio
- 12.5.5 Haisco Pharmaceutical Recent Developments
- 12.6 Beacon Pharma
- 12.6.1 Beacon Pharma Company Information
- 12.6.2 Beacon Pharma Business Overview
- 12.6.3 Beacon Pharma Revenue in Long-acting DPP-4 Inhibitor Drug Business (2020-2025)
- 12.6.4 Beacon Pharma Long-acting DPP-4 Inhibitor Drug Product Portfolio
- 12.6.5 Beacon Pharma Recent Developments
- 12.7 Baiji Dichang Pharmaceutical
- 12.7.1 Baiji Dichang Pharmaceutical Company Information
- 12.7.2 Baiji Dichang Pharmaceutical Business Overview
- 12.7.3 Baiji Dichang Pharmaceutical Revenue in Long-acting DPP-4 Inhibitor Drug Business (2020-2025)
- 12.7.4 Baiji Dichang Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio
- 12.7.5 Baiji Dichang Pharmaceutical Recent Developments
- 12.8 Furiex
- 12.8.1 Furiex Company Information
- 12.8.2 Furiex Business Overview
- 12.8.3 Furiex Revenue in Long-acting DPP-4 Inhibitor Drug Business (2020-2025)
- 12.8.4 Furiex Long-acting DPP-4 Inhibitor Drug Product Portfolio
- 12.8.5 Furiex Recent Developments
- 13 Report Conclusion
- 14 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.